Clinical Trial News and Research

RSS

BBC TV report profiles NW Bio's DCVax-L Phase III trial for GBM brain cancer

Northwest Biotherapeutics, Inc.("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the British Broadcasting Company (BBC) TV network has broadcast a report profiling the first European patient in the Company's Phase III clinical trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM), the most common and aggressive form of brain cancer.

31 Dec 2013

Most clinical trials of vitamin supplements have flawed methodology

Most large, clinical trials of vitamin supplements, including some that have concluded they are of no value or even harmful, have a flawed methodology that renders them largely useless in determining the real value of these micronutrients, a new analysis suggests.

31 Dec 2013

GRADE study evaluates four new medications for Type 2 diabetes

The GRADE study at the University of Alabama at Birmingham had a special visitor in November. Red suit. Black boots. White beard. Belly that shook like a bowl full of jelly. A V.I.E. (Very Important Elf) visited this national clinical trial for Type 2 diabetes.

31 Dec 2013

Study finds way to boost corneal transplant acceptance rate

For the estimated 10 percent of patients whose bodies reject a corneal transplant, the odds of a second transplant succeeding are poor. All that could change, however, based on a UT Southwestern Medical Center study that has found a way to boost the corneal transplant acceptance rate.

31 Dec 2013

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

Alliance for Cancer Gene Therapy grants nearly $25M to conduct cancer related gene therapy research

As the potential of gene and cell therapy in fighting cancers grows and oncologists across the nation explore the burgeoning science, doctors have uncovered a stunning development – cancers can be treated using patients' own cells as a weapon, and can eliminate the harrowing, often debilitating effects of chemotherapy, radiation and surgery.

28 Dec 2013

Cancer immunotherapy named 2013 Breakthrough of the Year by journal Science

Detect. Destroy. Remember. The mantra of the immune system's relentless campaign against infectious invaders and the body's own abnormal cells finally is applying to cancer in meaningful ways.

28 Dec 2013

Invivo Therapeutics receives FDA conditional approval to advance its first clinical trial

InVivo Therapeutics Holdings Corp. (NVIV) announced today that it has received conditional approval from the Food and Drug Administration for proposed changes to the protocol and supporting documents for the safety trial of its first investigational product, a degradable polymer scaffold for spinal cord injury.

27 Dec 2013

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

The I-SPY 2 TRIAL, a randomized phase II clinical trial for breast cancer launched through a unique partnership with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and sponsored by QuantumLeap Healthcare Collaborative has graduated the first two drugs from its innovative, multidrug standing platform trial.

27 Dec 2013

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

27 Dec 2013

CEL-SCI closes public offering of common stock, exercises over-allotment option to purchase additional shares

CEL-SCI Corporation, a late-stage oncology company, today announced that it has closed an underwritten public offering of units consisting of an aggregate of 5,238,095 shares of common stock and warrants to purchase an aggregate of 5,238,095 shares of common stock. The

27 Dec 2013

Stem cell-based gene therapy shows long-term outcomes for treatment of genetic skin diseases

Stem cell-based gene therapy holds promise for the treatment of devastating genetic skin diseases, but the long-term clinical outcomes of this approach have been unclear.

27 Dec 2013

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, UT Southwestern Medical Center researchers report.

27 Dec 2013

Researchers complete genomic analysis of cervical cancer in two patient populations

Researchers from the Boston area, Mexico, and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in cervical cancer, including at least one for which targeted treatments have been approved for other forms of cancer.

25 Dec 2013

Prolonged exposure therapy shows greater success for treating adolescent PTSD patients

Researchers at Penn Medicine report in the December 25 issue of JAMA that a modified form of prolonged exposure therapy - in which patients revisit and recount aloud their trauma-related thoughts, feelings and situations - shows greater success than supportive counseling for treating adolescent PTSD patients who have been sexually abused.

25 Dec 2013

Synergy Pharmaceuticals closes patient enrollment in plecanatide phase 2b clinical trial in IBS-C

Synergy Pharmaceuticals Inc. today announced it has closed patient enrollment in its plecanatide phase 2b clinical trial in irritable bowel syndrome with constipation.

24 Dec 2013

Concordia Healthcare acquires Pinnacle Biologics

Concordia Healthcare Corp., an integrated, specialty healthcare company focused on the acquisition of legacy pharmaceutical products and medical devices and the acquisition and/or development of orphan drugs, announced today that it has acquired Pinnacle Biologics, Inc., a U.S.-based biopharmaceutical company specializing in legacy pharmaceuticals which have the potential for development as orphan drugs to treat cancer indications in addition to those for which they have previously been approved.

24 Dec 2013

Actavis' subsidiary receives FDA complete response letter for progestin-only patch NDA

Actavis plc today confirmed that the Company's subsidiary has received a complete response letter from the U.S. Food and Drug Administration for its New Drug Application for a progestin-only transdermal contraceptive patch (Norethindrone Transdermal Delivery System) for use by women to prevent pregnancy.

24 Dec 2013

Acupuncture treatments may help alleviate side effects of breast cancer drugs

A new analysis has found that both real and sham acupuncture treatments may help alleviate side effects of drugs commonly used to treat breast cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help clinicians improve care for cancer patients. The results also raise the question of whether sham acupuncture is truly inert or may, like real acupuncture, have beneficial effects.

24 Dec 2013

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

Antisense Therapeutics Limited is pleased to advise that positive results have been achieved from the interim analysis of a subset of available data from its Phase II clinical trial of ATL1103 in patients with the growth disorder, acromegaly.

23 Dec 2013

Clinical Trial News and Research

BBC TV report profiles NW Bio's DCVax-L Phase III trial for GBM brain cancer

Most clinical trials of vitamin supplements have flawed methodology

GRADE study evaluates four new medications for Type 2 diabetes

Study finds way to boost corneal transplant acceptance rate

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Alliance for Cancer Gene Therapy grants nearly $25M to conduct cancer related gene therapy research

Cancer immunotherapy named 2013 Breakthrough of the Year by journal Science

Invivo Therapeutics receives FDA conditional approval to advance its first clinical trial

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

CEL-SCI closes public offering of common stock, exercises over-allotment option to purchase additional shares

Stem cell-based gene therapy shows long-term outcomes for treatment of genetic skin diseases

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

Researchers complete genomic analysis of cervical cancer in two patient populations

Prolonged exposure therapy shows greater success for treating adolescent PTSD patients

Synergy Pharmaceuticals closes patient enrollment in plecanatide phase 2b clinical trial in IBS-C

Concordia Healthcare acquires Pinnacle Biologics

Actavis' subsidiary receives FDA complete response letter for progestin-only patch NDA

Acupuncture treatments may help alleviate side effects of breast cancer drugs

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery